Has Diana Rabadi Marar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $25,462 in general payments to Diana Rabadi Marar, MD across 1,299 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Diana Rabadi Marar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Diana Rabadi Marar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Diana Rabadi Marar, MD

Internal Medicine · Council Bluffs, IANPI 1366458945

Payments from drug & device makers

$25,462in general payments, 2019–2025

Across 1,299 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$2K
Amgen$2K
Bayer$2K
AstraZeneca$2K
Novo Nordisk$2K
Novo Nordisk AS$2K
plus $13K from 54 others

$4,392in research payments, 2019–2025

Across 25 payments — averaging $175.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novo Nordisk AS$3K
Gilead$1K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	156	$2,178
Amgen	118	$2,084
Bayer	45	$1,987
AstraZeneca	74	$1,955
Novo Nordisk	109	$1,816
Novo Nordisk AS	4	$1,766
AbbVie(2 entities)	99	$1,445
Gilead	58	$1,136
Astellas Pharma US Inc	36	$1,070
Pfizer	63	$970
Johnson & Johnson	53	$845
Merck	39	$601
Novartis	35	$597
Sanofi-aventis U.S. LLC	33	$557
Amarin Pharma, Inc.	30	$554
GSK	41	$469
Takeda Pharmaceuticals U.S.A., Inc.	20	$412
Esperion Therapeutics, Inc.	28	$398
Boehringer Ingelheim	26	$385
Aimmune Therapeutics, Inc.	5	$348
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	23	$304
Medtronic(2 entities)	6	$283
Sumitomo Pharma America, Inc.	13	$242
E.r. Squibb & Sons, L.L.C.	15	$220
Otsuka America Pharmaceutical, Inc.	10	$213
Kowa Pharmaceuticals America, Inc.	13	$178
Mannkind Corporation	10	$166
Radius Health, Inc.	8	$142
Biohaven Pharmaceutical Holding Company Ltd.	9	$141
Eisai Inc.	6	$129
Mylan Specialty L.p.	8	$127
Xeris Pharmaceuticals, Inc.	8	$126
Biohaven Pharmaceuticals, Inc.	8	$124
Sunovion Pharmaceuticals Inc.	10	$122
Corcept Therapeutics	5	$91
Abbott	4	$87
Boston Scientific	3	$80
Axsome Therapeutics, Inc.	5	$78
Verona Pharma, Inc.	4	$70
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	3	$69
Lundbeck LLC	4	$69
Idorsia Pharmaceuticals US Inc	4	$67
Jazz Pharmaceuticals Inc.	3	$56
Nalpropion Pharmaceuticals LLC	4	$55
Biogen	3	$54
Vertex	2	$41
Ironwood Pharmaceuticals, Inc	2	$36
Regeneron Healthcare Solutions, Inc.	2	$35
Ascensia Diabetes Care US Inc.	2	$35
Azurity Pharmaceuticals, Inc.	2	$34
Arbor Pharmaceuticals, Inc.	2	$30
Ardelyx, Inc.	2	$30
Vanda Pharmaceuticals Inc.	2	$29
Mallinckrodt Hospital Products Inc.	1	$24
Ipsen Biopharmaceuticals, Inc	1	$24
VBI Vaccine (delaware) Inc.	1	$17
Recordati_rare_diseases_inc.	1	$17
Madrigal Pharmaceuticals	1	$17
Scpharmaceuticals Inc.	1	$16
Avanir Pharmaceuticals, Inc.	1	$16

How this compares

$25,462 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa →

Medicare billing

Part B allowed, 2024

$70,375

Medicare patients

107

Services billed

1,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Council Bluffs

Isam MararCouncil Bluffs$1.5M
Alan KricsfeldCouncil Bluffs$49K
Matthew FryzekCouncil Bluffs$28K
Barry KricsfeldCouncil Bluffs$13K
Vikrant SalariaCouncil Bluffs$7K
Kathleen JonesWest Des Moines$7.6M
Jennifer KillionAmes,$4.9M
Lena Rydberg FreeseWest Des Moines$1.8M
Mark JohnsonMason City$223K
Ryan TomlinsonDes Moines$209K

See the full list for Iowa →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →